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A B S T R A C T
To prepare new type of estrane hybrid molecules, we chose 3-methoxy- and 3-benzyloxy-17β,16β-epox-
ymethylene-estra-1,3,5(10)-trienes as starting materials (2 and 5). These steroid oxetanes were transformed with
ethylene glycol in the presence of BF3.OEt2 into 3-methoxy- and 3-benzyloxy-16β-(2′-oxa-4′-hydroxy)butyl-17β-
hydroxy-estra-1,3,5(10)-trien-17β-ols (3a and 6a). Iodination of the terminal hydroxy group aﬀorded iodo de-
rivatives 3b and 6b, which underwent one-pot 3-O-alkylation with unprotected ascorbic acid to yield 3c and 6c.
The same process with salicylic acid led to 2-O-alkylated salicylic acid derivatives 3d and 6d. Iodo derivatives 3b
and 6b underwent nucleophilic exchange reaction with NaN3 furnishing the corresponding azido compounds 3e
and 6e. These compounds were subjected to azide–alkyne CuAAC reactions with phenylacetylene and their p-
substituted derivatives to form 1,4-substituted triazoles 3f-h and 6f-h. The reduction of 3e and 6e with hy-
drazine hydrate in the presence of Raney Ni provided the corresponding amino derivatives 3i and 6i. These
compounds were reacted further with varied substituted benzoic acids to deliver terminal benzamido derivatives
3j-m and 6j-m.
We determined the in vitro antiproliferative activities of compounds 2, 5, 3a-m and 6a-m by means of MTT
assays on a panel of human adherent cancer cell lines A2780, MCF-7, MB-231 and SiHa.
1. Introduction
A signiﬁcant aim in organic chemistry is the development of new
type of pharmacologically active substances. The coupling of two or
more natural products to make hybrids leads to an almost inexhaustible
reservoir of new types of compounds with diverse structures [1]. Ster-
oids have become ideal synthons for the development of diverse con-
jugates due to their rigid framework and a potential for varying levels
of functionalization, broad biological activity proﬁle and the ability to
penetrate the cell membranes and bind to speciﬁc hormone receptors.
However, the number of steroidal natural products is limited, whereas
numerous hybrids as conjugates of steroids can be prepared. Medicinal
applications are based on the fact that biological activity of several new
hybrids exceeds that of the parent compounds [2,3].
As part of the research program of steroid hybrids, we were inter-
ested in the synthesis of various kinds of natural and unnatural com-
pounds, which are linked with the 2′-oxa-butyl side chain at position
16β of the estrane nucleus. Starting with 3-methoxy- and 3-benzyloxy-
estra-1,3,5(10)-trien-17-ones, product molecules with a 16β-(2′-oxa-4′-
hydroxy)butyl side chain were synthesized in ﬁve steps.
We set out to obtain answers to the following questions: (1) how the
antiproliferative activity against diﬀerent cancer cell lines in the 3-
methoxy- and 3-benzyloxy series diﬀer, and (2) what kind of natural (L-
ascorbic acid and salicylic acid) or unnatural compounds at the end of
side chain inﬂuence the characteristics of the antiproliferative activity.
2. Experimental
2.1. General
Melting points (mp) were determined on a Koﬂer apparatus and are
uncorrected. Speciﬁc rotations were measured in CHCl3 (c 1) at 20 °C
with a POLAMAT-A (Zeiss-Jena) polarimeter and are given in units of
10−1 deg cm2 g−1. Elementary analysis data were determined with a
PerkinElmer CHN analyzer model 2400. Reactions were monitored by
TLC on Kieselgel-G (Merck Si 254 F) layers (0.25 mm thick); solvent
systems (ss): (A) diisopropyl ether, (B) acetone/toluene/hexane
(30:35:35 v/v), (C) methanol/ethyl acetate (5:95 v/v). The spots were
https://doi.org/10.1016/j.steroids.2019.02.016
Received 17 January 2019; Received in revised form 20 February 2019; Accepted 26 February 2019
⁎ Corresponding author.
E-mail address: schneider@chem.u-szeged.hu (G. Schneider).
Steroids 148 (2019) 63–72
Available online 11 May 2019
0039-128X/ © 2019 Published by Elsevier Inc.
T
detected by spraying with 5% phosphomolybdic acid in 50% aqueous
H3PO4. Rf values were determined for the spots observed by illumina-
tion at 254 and 365 nm. Flash chromatography: silica gel 60, 40–63 μm.
All solvents were distilled immediately prior to use. NMR spectra were
recorded on a Bruker DRX 500 instrument at 500 (1H NMR) or 125MHz
(13C NMR). Chemical shifts are reported in ppm (δ scale) and coupling
constants (J) in Hz. For the determination of multiplicities, the J-MOD
pulse sequence was used.
2.2. 3-Methoxy-17β,16β-epoxymethylene-estra-1,3,5(10)-triene (2)
3-Methoxy-16β-p-toluenesulfonyloxymethyl-estra-1,3,5(10)-trien-
17β-ol (1) [4] (2.35 g, 5mmol) was dissolved in methanol (50ml) and
heated at reﬂux with NaOCH3 (450mg, 8mmol) for 2 h. The reaction
mixture was diluted with water, the precipitate was ﬁltered oﬀ, dried,
and crystallized from the mixture of acetone/hexane to give 2 (1.28 g,
86%). Mp: 164–165 °C; Rf = 0.60 (ss A); [α]D25=+74 (c 1 in CHCl3).
(Found: C, 80.65; H, 8.87. C20H26O2 (298.42) requires: C, 80.50; H,
8.78%). 1H NMR (δ, ppm, CDCl3): 1.12 (s, 3H, 18-H3), 2.87 (m, 2H, 6-
H2), 3.23 (dd, 1H, J=14.0 Hz, J=6.5 Hz, 16-H), 3.79 (s, 3H, 3-OCH3),
4.26 (t, 1H, J=6.0 Hz, 16a-H2), 4.65 (d, 1H, J=8.0 Hz, 17-H), 4.78 (t,
1H, J=6.0 Hz, 16a-H2), 6.64 (s, 1H, 4-H), 6.72 (dd, 1H, J=8.0 Hz,
J=2.0 Hz, 2-H), 7.21 (d, 1H, J=8.0 Hz, 1-H). 13C NMR (δ, ppm,
CDCl3): 12.8 (C-18), 27.0, 28.0, 29.8, 31.0, 37.3, 37.5, 38.4, 43.7, 44.8
(C-13), 54.5 (C-16), 55.2 (3-OCH3), 76.9 (C-16a), 95.6 (C-17), 111.5 (C-
2), 113.8 (C-4), 126.3 (C-1), 132.3 (C-10), 137.8 (C-5), 157.5 (C-3).
2.3. 3-Methoxy-16β-(2′-oxa-4′-hydroxy)butyl-17β-hydroxy-estra-
1,3,5(10)-triene (3a)
A solution of compound 2 (10.43 g, 35.0mmol) in 50ml CH2Cl2
gave two phases upon the addition of ethylene glycol (50ml). After
adding BF3·OEt2 (0.3 ml, 2 mmol) dropwise, the reaction mixture was
stirred at room temperature for 24 h then it was neutralized with
NaHCO3 and diluted with water. After extraction with toluene/ethyl
acetate (1:1 v/v), the organic layer was dried over Na2SO4 and eva-
porated in vacuo. The crude product after chromatography on silica gel
with ethyl acetate/CH2Cl2 (3:7 v/v) gave 3a (10.6 g, 84%). Mp:
113–115 °C; Rf = 0.45 (ss B); [α]D25=+45.1 (c 1 in CHCl3). (Found:
C, 73.45; H, 9.12. C22H32O4 (360.49) requires: C, 73.30; H, 8.95%). 1H
NMR (δ, ppm, CDCl3): 0.84 (s, 3H, 13-H3), 2.85 (m, 2H, 6-H2), 3.68 (m,
6H, 3× linker H2), 3.78 (s, 3H, 3-OCH3), 3.87 (dd, 1H, J=9.5 Hz,
J=4.0 Hz, 17-H), 6.63 (s, 1H, 4-H), 6.71 (dd, 1H, J=8.5 Hz, 2.0 Hz,
2-H), 7.21 (d, 1H, J=8.5 Hz, 1-H). 13C NMR (δ, ppm, CDCl3): 11.95 (C-
18), 26.4, 27.6, 28.3, 29.8, 38.0, 38.1, 40.2, 43.0 (linker CH2), 43.9,
44.2 (C-13), 49.1 (C-16), 55.2 (3-OCH3), 70.9 (linker CH2), 72.2 (linker
CH2), 82.2 (C-17), 111.4 (C-2), 113.8 (C-4), 126.3 (C-1), 132.7 (C-10),
137.8 (C-5), 157.4 (C-3).
2.4. 3-Methoxy-16β-(2′-oxa-4′-iodobutyl)estra-1,3,5(10)-trien-17β-ol
(3b)
Compound 3a (2.16 g, 6mmol), Ph3P (2.34 g, 9mmol), and imida-
zole (0.61 g, 9mmol) were dissolved in CH2Cl2 (50ml) and I2 (1.04 g,
9mmol) was added in portions. The reaction mixture, after stirring at
room temperature for 24 h, was washed with water and with dilute HCl
and NaHCO3 solutions. The organic phase was dried over Na2SO4 and
evaporated in vacuo. The crude product chromatographed on silica gel
with CH2Cl2/hexane (1:3 v/v) and ethyl acetate/CH2Cl2 (2.5:97.5 v/v
%) gave 3b (2.15 g, 76%). Mp: 77–80 °C; Rf = 0.80 (ss B);
[α]D25=+43.4 (c 1 in CHCl3). (Found: C, 56.38; H, 6.45. C21H31IO3
(470.38) requires: C, 56.17; H, 6.64%). 1H NMR (δ, ppm, DMSO‑d6):
0.68 (s, 3H, 18-H3), 2.76 (m, 2H, 6-H2), 2.44 (s, 2H, CH2-I), 3.58–3.66
(m, 4H, 2× linker H2), 3.68 (s, 3H, 3-OCH3), 4.47 (d, 1H, J=4.5 Hz,
17-H), 6.59 (s, 1H, 4-H), 6.66 (d, 1H, J=8.5 Hz, 2-H), 7.15 (d, 1H,
J=8.5 Hz, 1-H). 13C NMR (δ, ppm, DMSO‑d6): 5.8 (CH2-I), 12.3 (C-18),
25.9, 26.9, 29.2, 30.4, 37.1 (C-8), 37.9, 38.9, 43.4 (C-9), 43.5, 48.2 (C-
14), 54.7 (3-OCH3), 70.6 (linker CH2), 72.6 (linker CH2), 80.1 (C-17),
111.3 (C-2), 113.3 (C-4), 126.0 (C-1), 132.1 (C-10), 137.3 (C-5), 156.9
(C-3).
2.5. 3-Methoxy-16β-[2′-oxa-4′-(3″-acetyl-ascorbinyl)butyl]estra-
1,3,5(10)-trien-17β-acetate (3c)
Compound 3b (470mg, 1.00mmol) was dissolved in DMSO (8ml)
then NaHCO3 (242mg, 3mmol) and L-ascorbic acid (440mg, 2.5mmol)
were added. The yellow mixture was stirred for 6 h at 60 °C then it was
diluted with water and saturated with NH4Cl. The white precipitate was
ﬁltered, dried and then dissolved in the mixture of pyridine (2ml) and
acetic anhydride (2ml). After standing at room temperature for 24 h,
the solution was diluted with water and the oil separating out was
extracted with CH2Cl2 (3× 15ml). The organic phase was washed with
NaHCO3 solution and water then dried and evaporated in vacuo. The
crude product chromatographed on silica gel with CH2Cl2 aﬀorded 3c
(170mg, 43%). Mp: 54 °C; Rf = 0.4 (ss B); [α]D25=−5.1 (c 1 in
CHCl3). (Found: C, 63.15; H, 6.83. C36H46O13 (686.74) requires: C,
62.96; H, 6.75%). 1H NMR (δ, ppm, CDCl3): 0.84 (s, 3H, 18-H3),
2.07–2.27 (overlapping multiplets, 12H, 4×Ac-H3), 2.84 (m, 2H, 6-
H2), 3.77 (s, 3H, 3-OCH3), 5.43 (t, 1H, J=7.5 Hz, 17-H), 6.62 (s, 1H, 4-
H), 6,70 (dd, 1H, J=8.5 Hz, J=2.0 Hz, 2-H), 7.18 (d, 1H, J=8.5 Hz,
1-H). 13C NMR (δ, ppm, CDCl3): 13.0 (C-18), 20.2, 20.5, 20.6, 21.0,
21.0, 26.1, 27.3, 29.7, 29.7, 37.4, 37.8 (C-8), 38.0 (C-9), 43.5 (C-13),
43.7 (C-14), 48.7, 55.2 (3-OCH3), 62.1, 67.0, 68.3, 71.5, 72.6, 72.8,
74.2, 81.9 (C-17), 111.5 (C-2), 113.8 (C-4), 126.3 (C-1), 132.3 (C-5),
137.8 (C-10), 157.5 (C-3), 159.1, 166.5, 167.7, 169.9, 170.9.
2.6. 3-Methoxy-16β-[2′-oxa-4′-butyl-(2″-salicylic acidyl)]-17β-hydroxy-
estra-1,3,5(10)-triene (3d)
Compound 3b (470mg, 1mmol) was dissolved in DMSO (8ml) then
NaHCO3 (242mg, 3mmol) and salicylic acid (345mg, 2.5mmol) were
added. The yellow mixture was stirred for 6 h at 60 °C. It was then di-
luted with water and the white precipitate separating out was separated
by ﬁltration. The residue obtained was chromatographed on silica gel
with CH2Cl2 to give 3d (119mg, 24%). Mp: 134–136 °C; Rf = 0.25 (ss
B); [α]D25=+64.7 (c 1 in CHCl3). (Found: C, 72.56; H, 7.72 C29H36O6
(480.59) requires: C, 72.48; H, 7.55%). 1H NMR (δ, ppm, CDCl3): 0.64
(s, 3H, 18-H3), 2.72 (m, 2H, 6-H2), 3.67 (s, 3H, 3-OCH3), 3.67–4.44
(overlapping multiplets, 6H, 3× linker H2), 4.49 (d, 1H, J=4.0 Hz,
17-H), 6.58 (s, 1H, 4-H), 6.63 (dd, 1H, J=8.5 Hz, J=2.0 Hz, 2-H),
6.93 (t, 1H, J=7.5 Hz, 5″-H), 6.97 (d, 1H, J=8.5 Hz, 6″-H), 7.12 (d,
1H, J=8.5 Hz, 1-H), 7.52 (t, 1H, J=8.5 Hz, 4″-H), 7.79 (d, 1H,
J=7.5 Hz, 3″-H). 13C NMR (δ, ppm, CDCl3): 12.2 (C-18), 26.0, 26.9,
29.2, 30.2, 37.2, 38.0, 43.4 (C-9), 43.5, 48.2 (C-14), 54.8 (3-OCH3),
64.2 (linker CH2), 67.8 (linker CH2), 73.0 (linker CH2), 80.1 (C-17),
111.4 (C-2), 113.3 (C-2″), 113.3 (C-4), 117.3, 119.3, 126.0, 129.9,
132.0 (C-10), 137.3 (C-5), 156.9 (C-1″), 160.1 (C-3), 168.6 (COOH).
2.7. 3-Methoxy-16β-(2′-oxa-4′-azidobutyl)estra-1,3,5(10)-trien-17β-ol
(3e)
Compound 3b (2.30 g, 5mmol) was dissolved in N,N-di-
methylformamide (50ml). After adding NaN3 (1.62 g, 25mmol) the
reaction mixture was stirred for 6 h at 100 °C then diluted with water.
The white precipitate separating out was ﬁltered to give 3e (2.4 g,
83%). Mp: 88–89 °C; Rf = 0.85 (ss B); [α]D25=+48.8 (c 1 in CHCl3).
(Found: C, 68.43; H, 8.34. C22H31N3O3 (385.50) requires: C, 68.54; H,
8.11%). 1H NMR (δ, ppm, CDCl3): 0.83 (s, 3H, 18-H3), 2.85 (m, 2H, 6-
H2), 3.43 (t, 2H, J=5.0 Hz, linker H2), 3.63 (m, 4H, 2× linker H2),
3.78 (s, 3H, 3-OCH3), 3.88 (d, 1H, J=10.0 Hz, 17-H), 6.63 (d, 1H,
J=2.0 Hz, 4-H), 6.71 (dd, 1H, J=8.5 Hz, J=2.0 Hz, 2-H), 7.21 (d,
1H, J=8.5 Hz, 1-H). 13C NMR (δ, ppm, CDCl3): 12.0 (C-18), 26.4, 27.5,
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28.4, 29.8, 37.9, 38.1, 40.2, 43.8, 44.2 (C-13), 49.0, 50.8 (N-CH2), 55.2
(3-OCH3), 69.5 (linker CH2), 72.5 (linker CH2), 82.2 (C-17), 111.4 (C-
2), 113.7 (C-4), 126.3 (C-1), 132.7 (C-10), 137.8 (C-5), 157.4 (C-3).
2.8. General procedure for the synthesis of triazoles (3f-h and 6f-h)
Compound 3e (385.5mg, 1mmol) or 6e (461.6 mg, 1mmol) was
dissolved in CH2Cl2 (20ml), then CuI (19mg, 0.1mmol), Et3N (0.2ml,
2 mmol), and an appropriate terminal alkyne (2mmol) were added. The
mixture was stirred under reﬂux for 24 h, then it was diluted with water
(30ml) and extracted with CH2Cl2 (2×30ml). The combined organic
phase was dried over Na2SO4 and evaporated in vacuo. The crude
product was puriﬁed by ﬂash chromatography using ethyl acetate/
CH2Cl2 in diﬀerent concentrations.
2.8.1. 3-Methoxy-16β-[(2′-oxa-4′-(4″-phenyl)-1″H-1″,2″,3″-triazol-1″-
yl]butyl-estra-1,3,5(10)-17β-ol (3f)
Compound 3e (385mg, 1mmol) and phenylacetylene (0.22 ml)
were used for the synthesis as described in Section 2.8. The crude
product was chromatographed on silica gel with ethyl acetate/CH2Cl2
(2:98 v/v%) to yield pure 3f (250.5mg, 51%) as white solid. Mp:
153–154 °C; Rf = 0.3 (ss B); [α]D25=+33.8 (c 1 in CHCl3). (Found: C,
74.02; H, 7.55. C30H37N3O3 (487.63) requires: C, 73.89; H, 7.65%).
Characterization of the compound was performed as its derivative
Compound 3f (100mg, 0.21mmol) was dissolved in the mixture of
pyridine (2ml) and acetic anhydride (2ml) and the solution was al-
lowed to stand at room temperature for 12 h followed by dilution with
water. The white precipitate separating out was ﬁltered oﬀ, washed
thoroughly with water and dried to deliver the required acetyl deri-
vative (95mg, 86%). (Found: C, 72.75; H, 7.28. C32H39N3O4 (529.67)
requires: C, 72.56; H, 7.42%). 1H NMR (δ, ppm, CDCl3): 0.82 (s, 3H, 18-
H3), 1.99 (s, 3H, Ac-H3), 2.80 (m, 2H, 6-H2), 2.28–3.82 (overlapping
multiplets, 4H, 2× linker H2), 3.77 (s, 3H, 3-OCH3), 4.56 (m, 2H, 16a-
H2), 4.85 (d, 1H, J=10.0 Hz, 17-H), 6.62 (s, 1H, 4-H), 6.70 (d, 1H,
J=8.5 Hz, 2-H), 7.18 (d, 1H, J=8.5 Hz, 1-H), 7.34 (t, 1H, J=7.0 Hz,
4″-H), 7.43 (t, 2H, J=7.0 Hz, 3″- and 5″-H), 7.88 (d, 2H, J=7.0 Hz,
2″- and 6″-H), 7.97 (s, 1H, 5′-H). 13C NMR (δ, ppm, CDCl3): 13.0 (C-18),
20.9, 26.1, 27.2, 29.7, 29.7, 37.4, 37.9, 38.2, 43.4 (linker CH2), 43.6,
48.6 (C-16), 50.7 (C-13), 55.2 (3-OCH3), 69.1 (linker CH2), 72.6 (C-
16a), 81.9 (C-17), 111.5 (C-2), 113.7 (C-4), 121.4 (triazol CH), 125.7
(C-2′ and -6′), 126.3 (C-1), 128.1 (C-4′), 128.8 (C-3′ and -5′), 130.4 (C-
1′), 132.2 (C-10), 137.7 (C-5), 147.4 (triazol C), 157.4 (C-3), 171.0 (Ac-
C]O).
2.8.2. 3-Methoxy-16β-[2′-oxa-4′(4″-p-tolyl)-1″H-1″,2″,3″-triazol-1″-yl]
butyl-estra- 1,3,5(10)-17β-ol (3 g)
Compound 3e (385mg, 1mmol) and p-tolylacetylene (0.22 ml)
were used for the synthesis as described in Section 2.8. The crude
product was chromatographed on silica gel with ethyl acetate/CH2Cl2
(5:95 v/v%) to yield pure 3 g (250mg, 51%) as white solid. Mp:
159–160 °C;
Rf = 0.35 (ss B); [α]D25=+33.7 (c 1 in CHCl3). (Found: C, 74.38;
H, 7.95. C31H39N3O3 (501.66) requires: C, 74.22; H, 7.84%). 1H NMR
(δ, ppm, CDCl3): 0.78 (s, 3H, 18-H3), 2.38 (s, 3H, 4′-H3), 2.81 (m, 2H, 6-
H2), 3.78 (s, 3H, 3-OCH3), 6.62 (s, 1H, 4-H), 6.71 (d, 1H, J=8.0 Hz, 2-
H), 7.18 (s, 1H, 1-H), 7.21 (m, 2H, 3′- and 5′-H), 7.72 (d, 2H,
J=7.5 Hz, 2′- and 6′-H), 7.86 (s, 1H, 5′-H). 13C NMR (δ, ppm, CDCl3):
12.0 (C-18), 21.2, 26.3, 27.4, 28.7, 29.7, 37.7, 38.0 (C-8), 40.1 (C-9),
43.8 (C-14), 44.5 (C-13), 48.9 (C-16), 50.2, 55.1 (3-OCH3), 69.3, 72.6,
82.0 (C-17), 111.4 (C-2), 112.4, 113.7 (C-4), 120.3 (triazol CH) 125.6
(C-2′ and -6′), 126.2 (C-4′), 127.7, 129.5 (C-3′ and -5′), 132.5 (C-10),
137.8 (C-5), 137.9 (triazol C), 157.4 (C-3).
2.8.3. 3-Methoxy-16β-[2′-oxa-4′(4″-p-methoxyphenyl)-1″H-1″,2″,3″-
triazol-1″-yl]butyl-estra-1,3,5(10)-17β-ol (3 h)
Compound 3e (385.5mg, 1mmol) and p-methoxyphenylacetylene
(0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (5:95 v/v%) to yield pure 3 h (282.6mg, 55%) as white solid.
Mp: 151–152 °C; Rf = 0.30 (ss B); [α]D25=+18.7 (c 1 in CHCl3).
(Found: C, 72.07; H, 7.72. C31H39N3O4 (517.66) requires: C, 71.93; H,
7.59%). 1H NMR (δ, ppm, CDCl3): 0.78 (s, 3H, 18-H3), 2.81 (m, 2H, 6-
H2), 3.77 (s, 3H, 3-OCH3), 3.84 (s, 3H, 4″-OCH3), 3.67–4.56 (over-
lapping multiplets, 6H, 3× linker H2), 6.62 (s, 1H, 4-H), 6.71 (d, 1H,
J=8.5 Hz, 2-H), 6.95 (d, 2H, J=7.5 Hz, 3″- and 5″-H), 7.19 (d, 1H,
J=8.5 Hz, 1-H), 7.76 (d, 2H, J=7.5 Hz, 2″- and 6″-H). 13C NMR (δ,
ppm, CDCl3): 12.0 (C-18), 26.3, 27.5, 28.7, 29.7, 37.8, 38.0 (C-8), 40.2
(C-9), 43.9 (C-14), 44.2 (C-13), 48.9 (C-16), 50.3 (N-CH2), 55.2 (3-
OCH3), 55.3 (4″-OCH3), 69.3 (linker CH2), 72.7 (linker CH2), 82.0 (C-
17), 111.4 (C-2), 113.7 (C-4), 114.2 (C-2″ and -6″), 123.2 (C-1″), 126.2
(C-1), 127.0 (C-3″ and -5″), 132.5 (C-10), 137.8 (C-5), 157.4 (triazol C),
159.6 (C-3).
2.9. 3-Methoxy-16β-(2′-oxa-4′-aminobutyl)estra-1,3,5(10)-trien-17β-ol
(3i)
Compound 3e (2.40 g, 6.20mmol) was dissolved in ethanol
(120ml) and then hydrazine hydrate (98%, 6ml) was added to the
solution followed by the addition of Raney nickel (1.0 g) in small por-
tions. After completion of the reaction (monitored by TLC), the catalyst
was ﬁltered oﬀ and the ﬁltrate was diluted with water. The white
precipitate separating out was ﬁltered oﬀ, washed and dried to yield 3i
(1.98 g, 89%). Mp: 241–243 °C. The acetate derivative of the product
was used for characterization. Crude compound 3i (130mg, 0.5mmol)
was dissolved in the mixture of pyridine (2ml) and acetic anhydride
(2ml). The solution was allowed to stand at room temperature for 12 h
and then it was diluted with water. The white precipitate separating out
was ﬁltered oﬀ, washed thoroughly with water and dried to aﬀord the
acetylated compound (215mg, 97%). Mp: 134–135 °C; Rf = 0.85 (ss B);
[α]D25=+25.0 (c 1 in CHCl3). (Found: C, 70.55; H, 8.26. C26H37NO5
(443.58) requires: C, 70.40; H, 8.41%). 1H NMR (δ, ppm, DMSO‑d6):
0.79 (s, 3H, 18-H3), 1.79 (s, 3H, Ac-H3), 2.02 (s, 3H, Ac-H3), 2.77–3.43
(overlapping multiplets, 6H, 3× linker H2), 3.68 (s, 3H, 3-OCH3), 4.76
(d, 1H, J=10.0 Hz, 17-H), 6.61 (s, 1H, 4-H), 6.67 (d, 1H, J=8.5 Hz, 2-
H), 7.14 (d, 1H, J=8.5 Hz, 1-H), 7.81 (brs, 1H, NH). 13C NMR (δ, ppm,
DMSO‑d6): 12.7 (C-18), 20.6 (Ac-CH3), 22.5 (Ac-CH3), 25.7, 26.8, 29.1,
29.2, 29.3, 36.9 (N-CH2), 37.5 (C-8), 37.6 (C-9), 38.5, 42.8 (C-13), 43.0
(C-14), 47.8 (C-16), 54.7 (3-OCH3), 68.8 (linker CH2), 71.5 (linker
CH2) 81.1 (C-17), 111.3 (C-2), 113.3 (C-4), 126.0 (C-1), 131.7 (C-10),
137.2 (C-5), 156.9 (C-3), 169.0 (C]O), 170.0 (C]O).
2.10. General procedure for the synthesis of benzamido compounds (3j-m
and 6j-m)
1mmol of substituted aromatic carboxylic acids was dissolved in
DMF (5ml), HOBT (1-hydroxy-benzotriazol hydrate, 135mg,
1.1 mmol), HBTU [O-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium
hexaﬂuorophosphate, 379mg, 1.1 mmol] and DIPEA (0.172ml). The
mixture was stirred for 15min and compound 3i (359mg, 1mmol) or
6i (436mg, 1mmol) was added. After completion of the reaction in 3 h,
the solution was poured into water and saturated with NH4Cl. The re-
sulting emulsion was extracted with ethyl acetate/toluene (1:1 v/v), the
organic phase was dried over Na2SO4 and evaporated in vacuo. The
crude product was puriﬁed by ﬂash chromatography using ethyl
acetate/CH2Cl2 in diﬀerent ratios.
2.10.1. 3-Methoxy-16β-[2′-oxa-4′(4″-nitro)benzamido]butylestra-
1,3,5(10)-trien-17β-ol (3j)
Compound 3i (359mg, 1mmol) and 4-nitrobenzoic acid (167mg,
1mmol) were used for the synthesis as described in Section 2.10. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (2.5:97.5 v/v%) to yield pure 3j (199mg, 84%) as yellow solid.
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Mp: 156–157 °C; Rf = 0.50 (ss C); [α]D25=+10.2 (c 1 in CHCl3).
(Found: C, 68.72; H, 7.02. C29H36N2O6 (435.60) requires: C, 68.48; H,
7.13%). 1H NMR (δ, ppm, CDCl3): 0.81 (s, 3H, 18-H3), 2.83 (m, 2H, 6-
H2), 3.60–3.92 (overlapping multiplets, 6H, 3× linker H2), 3.77 (s, 3H,
3-OCH3), 3.90 (d, 1H, J=9.5 Hz, 17-H), 6.62 (s, 1H, 4-H), 6.70 (d, 1H,
J=6.0 Hz, 2-H), 7.09 (brs, 1H, NH), 7.19 (d, 1H, J=8.5 Hz, 1-H), 8.26
(m, 4H, 2′-, 3′-, 5′- and 6′-H). 13C NMR (δ, ppm, CDCl3): 12.2 (C-18),
26.3, 27.5, 28.5, 29.7, 37.7, 38.1 (C-8), 39.8 (C-9), 39.9 (N-CH2), 43.8
(C-14), 44.2 (C-13), 48.9 (C-16), 55.1 (3-OCH3), 69.3 (linker CH2), 72.5
(linker CH2), 82.4 (C-17), 111.4 (C-2), 113.7 (C-4), 123.5 (C-1), 123.7
(C-2′ and -6′), 128.2 (C-3′ and -5′), 131.0 (C-10), 132.4 (C-10), 137.4
(C-5), 140.0 (C-1′), 149.5 (C-4′), 157.4 (C-3), 165.7 (C]O).
2.10.2. 3-Methoxy-16β-[2′-oxa-4′(3″,5″-dinitro)benzamido]butyl-estra-
1,3,5(10)-trien-17β-ol (3 k)
Compound 3i (359mg, 1.0mmol) and 3,5-dinitrobenzoic acid
(212mg, 1mmol) were used for the synthesis as described in Section
2.10. The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (2.5:97.5 v/v%) to give pure 3 k (210mg, 38%) as
yellow solid. Mp: 225–227 °C; Rf = 0.55 (ss C); [α]D25=+15.8 (c 1 in
CHCl3). (Found: C, 63.08; H, 6.45. C29H36N3O8 (553.60) requires: C,
62.92; H, 6.37%). 1H NMR (δ, ppm, CDCl3): 0.82 (s, 3H, 18-H3),
3.59–3.95 (overlapping multiplets, 6H, 3x linker H2), 3.76 (s, 3H, 3-
OCH3), 6.61 (s, 1H, 4-H), 6.70 (d, 1H, J=8.5 Hz, 2-H), 7.18 (d, 1H,
J=8.5 Hz, 1-H), 7.68 (brs, 1H, NH) 9.11 (m, 3H, 2′-, 4′- and 6′-H). 13C
NMR (δ, ppm, CDCl3): 12.2 (C-18), 26.2, 27.5, 28.3, 29.7, 37.6, 38.0 (C-
8), 39.9 (C-9), 40.1 (N-CH2), 43.8 (C-14), 44.2 (C-13), 48.8 (C-16), 55.1
(3-OCH3), 68.6 (linker CH2), 71.8 (linker CH2), 82.6 (C-17), 111.4 (C-
2), 113.7 (C-4), 120.9 (C-1), 126.2 (C-4′), 127.4 (C-2′ and -6′), 132.4 (C-
10), 137.8 (C-5), 137.8 (C-1′), 148.5 (C-3′ and -5′), 157.4 (C-3), 162.6
(C]O).
2.10.3. 3-Methoxy-16β-[2′-oxa-4′(4″-methoxy)benzamido]butyl-estra-
1,3,5(10)-trien-17β-ol (3 l)
Compound 3i (359mg, 1.0 mmol) and 4-methoxybenzoic acid
(152mg, 1.00mmol) were used for the synthesis as described in Section
2.10. The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (2.5:97.5 v/v%) to yield pure 3 l (260mg, 53%) as
yellow oil. Rf = 0.55 (ss C); [α]D25=−73.8 (c 1 in CHCl3). (Found: C,
73.12; H, 7.85. C30H39NO5 (493.63) requires: C, 72.99; H, 7.96%). 1H
NMR (δ, ppm, CDCl3): 0.80 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2),
3.54–3.88 (overlapping multiplets, 6H, 3× linker H2), 3.77 (s, 3H, 3-
OCH3), 3.81 (s, 3H, 4″-CH3), 6.62 (d, 1H, J=2.0 Hz, 4-H), 6.70 (dd,
1H, J=8.5 Hz, J=2.5 Hz, 2-H), 6.86 (d, 2H, J=8.5 Hz, 3′- and 5′-H),
7.72 (d, 2H, J=8.5 Hz, 2′- and 6′-H), 6.78 (brs, 1H, NH), 7.19 (d, 1H,
J=8.5 Hz, 1H). 13C NMR (δ, ppm, CDCl3): 12.1 (C-18), 26.3, 27.5,
28.5, 29.8, 37.9, 38.1 (C-8), 39.8 (N-CH2), 39.9 (C-9), 43.8 (C-14), 44.1
(C-13), 48.9 (C-16), 55.2 (4″-OCH3), 55.3 (3-OCH3), 69.6 (linker CH2),
72.3 (linker CH2), 82.4 (C-17), 111.4, 111.8 (C-2), 113.7 (C-2′ and -6′),
116.1 (C-4), 126.6 (C-1), 128.8 (C-3′ and -5′), 132.5 (C-10), 137.8 (C-
1″), 139.0 (C-5), 157.4 (C-3), 162.2 (C-4″), 167.7 (C]O).
2.10.4. 3-Methoxy-16β-[2′-oxa-4′(3″,4″,5″-trimethoxy)benzamidobutyl]-
estra-1,3,5(10)-trien-17β-ol (3m)
Compound 3i (359mg, 1mmol) and 3,4,5-trimethoxybenzoic acid
(212mg, 1mmol) were used for the synthesis as described in Section
2.10. The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (10:90 v/v%) to yield pure 3m (450mg, 81%) as oil.
The acetate derivative was used for characterization. The crude com-
pound (450mg, 0.81mmol) was dissolved in the mixture of pyridine
(2ml) and acetic anhydride (2ml) and the solution was allowed to
stand at room temperature for 12 h. It was then diluted with water, the
white precipitate separating out was ﬁltered oﬀ, washed thoroughly
with water and dried to provide the acetylated compound (473mg,
98%). Mp: 55–56 °C; Rf = 0.80 (ss B); [α]D25=+5.0 (c 1 in CHCl3).
(Found: C, 68.73; H, 7.42. C34H45NO8 (595.72) requires: C, 68.55; H,
7.61%. 1H NMR (δ, ppm, CDCl3): 0.87 (s, 3H, 18-H3), 2.00 (s, 3H, Ac-
H3), 2.84 (m, 2H, 6-H2), 3.23–3.92 (overlapping multiplets, 6H, 3×
linker H2), 3.77 (s, 3H, 3-OCH3), 3.88 (s, 3H, 4′-OCH3), 3.92 (s, 6H, 3′-
and 5′-OCH3), 4.80 (d, 1H, J=10.0 Hz, 17-H), 6.62 (s, 1H, 4-H), 6.70
(dd, 1H, J=8.5 Hz, J=2.5 Hz, 2-H), 7.00 (brs, 1H, NH). 13C NMR (δ,
ppm, CDCl3): 13.0 (C-18), 21.2 (Ac-H3), 26.0, 27.4, 29.1, 29.7, 38.0 (C-
8), 38.1 (C-9), 40.2 (N-CH2), 43.2 (C-13), 43.6 (C-14), 48.6, 55.2, 56.3
(3-OCH3), 60.8, 69.4 (linker CH2), 72.2 (linker CH2), 82.0 (C-17), 104.6
(C-2′ and -6′), 107.3, 111.5 (C-2), 113.8 (C-4), 126.2 (C-1), 129.5,
132.2 (C-10), 137.7 (C-5), 156.0 (C-3).
2.11. 3-Benzyloxy-17β,16β-epoxymethylen-estra-1,3,5(10)-triene (5)
3-Benzyloxy-16β-bromomethyl-estra-1,3,5(10)-trien-17β-ol (4)
(2.27 g, 5mmol) [3] was used for the synthesis as described in Section
2.2. The crude product was crystallized from the mixture of acetone/
hexane to give 5 (1.60 g, 85%). Mp: 132 °C; Rf = 0.55 (ss A);
[α]D25=+60.4 (c 1 in CHCl3). (Found: C, 83.54; H, 7.92. C26H30O2
(374.52) requires: C, 83.38; H, 8.07%. 1H NMR (δ, ppm, CDCl3): 1.12
(s, 1H, 18-CH3), 2.86 (m, 2H, 6-H2), 4.27 (t, 1H, J=6.0 Hz, 16a-H2),
4.66 (d, 1H, J=8.0 Hz, 17-H), 4.78 (t, 1H, J=6.0 Hz, 16a-H2), 5.04 (s,
2H, Bn-H2), 6.73 (s, 1H, 4-H), 6.79 (dd, 1H, J=8.5 Hz, J=2.0 Hz, 2-
H), 7.21 (d, 1H, J=8.5 Hz, 1-H), 7.33 (d, 1H, J=7.0 Hz, 4′-H), 7.39 (t,
2H, J=7.5 Hz, 3′- and 5′-H), 7.44 (d, 2H, J=7.5 Hz, 2′- and 6′-H). 13C
NMR (δ, ppm, CDCl3): 12.8 (C-18), 27.0, 28.0, 29.9, 31.1, 37.3 (C-8),
37.6, 38.4 (C-9), 43.8 (C-14), 44.9 (C-13), 54.6 (C-16), 70.0 (Bn-CH2),
77.1 (C-16a), 95.6 (C-17), 112.4 (C-2), 114.9 (C-4), 126.4 (C-10), 126.4
(C-1), 127.5 (C-2′ and -6′), 127.9 (C-4′), 128.6 (C-3′ and -5′), 132.9 (C-
5), 137.4 (C-1), 156.8 (C-3).
2.11.1. 3-Benzyloxy-16β-(2′-oxa-4′hydroxy)butyl-17β-hydroxy-estra-
1,3,5(10)-triene (6a)
Compound 5 (13.1 g, 35mmol) was used for the synthesis as de-
scribed in Section 2.2. The crude product was chromatographed on
silica gel with ethyl acetate/CH2Cl2 (1:3 v/v) giving 6a (7.21 g, 77%).
Mp: 162.5–164.5 °C; Rf = 0.40 (ss B); [α]D25=+43.4 (c 1 in CHCl3).
(Found: C, 76.92; H, 8.46. C28H36O4 (436.58) requires: C, 77.03; H,
8.31%. 1H NMR (δ, ppm, CDCl3) in diacetate form: 0.85 (s, 3H, 18-H3),
2.08 (d, 6H, J=3.5 Hz, 17-OAc and 3′-OAc), 4.19 (t, 2H, J=9.5 Hz,
2″-H2), 4.88 (d, 1H, J=10.0 Hz, 17-H), 5.03 (s, 2H, Bn-H2), 6.72 (s,
1H, 4-H), 6.77 (dd, 1H, J=8.5 Hz, 2-H), 7.19 (d, 1H, J=8.5 Hz, 1-H),
7.30 (s, 1H, 4′-H), 7.37 (t, 2H, J=7.5 Hz, 3′- and 5′-H), 7.42 (d, 2H,
J=7.5 Hz, 2′- and 6′-H). 13C NMR (δ, ppm, CDCl3): 13.0 (C-18), 21.0
(17-OAc and ω-OAc), 26.1, 27.3, 29.7, 29.7, 37.5, 37.5, 38.0, 43.5 (C-
13), 43.7 (C-14), 48.8 (C-16), 63.6 (linker CH2), 68.5 (linker CH2), 70.0
(linker CH2), 72.5 (Bn-CH2), 81.9 (C-17), 112.3 (C-2), 114.8 (C-4),
126.3 (C-1), 127.4 (C-2′ and -6′), 127.8 (C-4′), 128.5 (C-3′ and -5′),
132.7 (C-10), 137.3 (C-1′), 137.9 (C-5), 156.8 (C-3), 170.9 (2×C]O).
2.11.2. 3-Benyzloxy-16β-(2′-oxa-4′-iodo)butyl-estra-1,3,5(10)-trien-17β-
ol (6b)
Compound 6a was dissolved in CH2Cl2 (50ml) and I2 (4.16 g,
36mmol) was added in portions. The reaction mixture was stirred at
room temperature for 24 h then washed with water, with dilute HCl and
NaHCO3 solutions. The organic phase was dried over Na2SO4 and
evaporated in vacuo. The crude product was chromatographed on silica
gel with CH2Cl2/hexane (1:3 v/v) and ethyl acetate/CH2Cl2 (2.5:97.5
v/v%) to obtain 6b (5.1 g, 47%). Mp: 108–110 °C; Rf = 0.75 (ss B);
[α]D25=+35.7 (c 1 in CHCl3). (Found: C, 61.32; H, 6.34. C28H35IO3
(546.48) requires: C, 61.54; H, 6.46%). 1H NMR (δ, ppm, CDCl3): 0.85
(s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.28–3.88 (m, 6H, 3× linker H2),
5.03 (s, 2H, Bn-H2), 6.72 (s, 1H, 4-H), 6.79 (dd, 1H, J=8.5 Hz,
J=2.5 Hz, 2-H), 7.21 (d, 1H, J=8.5 Hz, 1-H), 7.26 (s, 1H, 4′-H), 7.38
(t, 2H, J=7,5 Hz, 3′- and 5′-H), 7.42 (d, 2H, J=7.5 Hz, 2′- and 6′-H).
13C NMR (δ, ppm, CDCl3): 3.3 (CH2-I), 12.1 (C-18), 26.3, 27.5, 28.4,
29.7, 37.9, 38.1 (C-8), 40.2 (C-9), 43.9 (C-14), 44.2 (C-13), 49.0 (C-16),
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69.9, 71.3, 71.9, 82.2 (C-17), 112.2 (C-2), 114.8 (C-4), 126.3 (C-4′),
127.4 (C-2′ and -6′), 127.8 (C-1), 128.5 (C-3′ and -5′), 133.0 (C-10),
137.3 (C-1′) 137.9 (C-5), 156.7 (C-3).
2.11.3. 3-Benzyloxy-16β-[2′-oxa-4′-(3″-acetylascorbinyl)butyl]estra-
1,3,5(10)-trien-17β-acetate (6c)
Compound 6b (546mg, 1.00mmol) was dissolved in DMSO (8ml)
then NaHCO3 (242mg, 3.00mmol) and L-ascorbic acid (440mg,
2.50mmol) were added. The yellow mixture was stirred for 6 h at 60 °C
then it was diluted with water and saturated with NH4Cl. The white
precipitate was ﬁltered and dried. The resulting product was dissolved
in a mixture of pyridine (2ml) and acetic anhydride (2ml) and the
solution was allowed to stand at room temperature for 12 h. The re-
action mixture was then diluted with water and the oil separating out
was extracted with CH2Cl2 (3× 15ml). The organic phase was washed
with NaHCO3 solution and water, dried and evaporated in vacuo. The
crude product was chromatographed on silica gel with CH2Cl2 to obtain
6c (199mg, 46%). Mp: 58–60 °C; Rf = 0.4 (ss B); [α]D25=−5.3 (c 1 in
CHCl3). (Found: C, 65.93; H, 6.75. C42H50O13 (762.84) requires: C,
66.13; H, 6.61%. 1H NMR (δ, ppm, CDCl3): 0.85 (s, 3H, 18-H3),
2.07–2.11 (m, 12H 4×Ac-H3), 2.85 (m, 2H, 6-H2), 3.00–4.70 (m, 6H,
3× linker CH2), 5.03 (s, 2H, Bn-H2), 5.43 (s, 1H, 17-H), 6.72 (s, 1H, 4-
H), 6.77 (t, 1H, J=8.0 Hz, 2-H), 7.19 (d, 1H, J=8.0 Hz, 1-H), 7.38 (t,
2H, J=7.5 Hz, 3′- and 5′-H), 7.41 (d, 2H, J=7,5 Hz, 2′- and 6′-H). 13C
NMR (δ, ppm, CDCl3): 13.0 (C-18), 20.1–20.6 (4×Ac-CH3), 26.0, 29.6,
37.4, 37.7 (C-8), 37.9 (C-9), 43.4, 43.7 (C-14), 48.7 (C-16), 62.0, 67.0,
68.2, 69.9, 71.4, 72.8, 74.2, 81.9 (C-17), 112.3 (C-4), 114.8 (C-10),
114.8 (C-2), 126.2 (C-1), 127.4 (C-2′ and -6′), 127.8 (C-4), 128.5 (C-3′
and -5′), 132.6 (C-5), 137.8 (C-3).
2.11.4. 3-Benzyloxy-16β-[2′-oxa-4′-butyl-(2″-salicylic acidyl)]-17β-
hydroxy-estra-1,3,5(10)-triene (6d)
Compound 6b (546mg, 1mmol) was dissolved in DMSO (8ml) then
NaHCO3 (242mg, 3mmol) and salicylic acid (345mg, 2.5 mmol) were
added. The yellow mixture was stirred for 6 h at 60 °C. It was then di-
luted with water and saturated with NH4Cl. The resulting product was
chromatographed on silica gel with ethyl acetate/CH2Cl2 (2.5:77.5 v/v
%) to aﬀord 6d (250mg, 45%). Mp: 97–99 °C; Rf = 0.30 (ss B);
[α]D25=+32.0 (c 1 in CHCl3). (Found: C, 75.34; H, 7.36. C35H40O6
(556.69) requires: C, 75.51; H, 7.24%). 1H NMR (δ, ppm, CDCl3): 0.81
(s, 3H, 18-H3), 2.66 (m, 2H, 6-H2), 3,67–4,50 (overlapping multiplets,
6H, 3× linker H2), 5.03 (s, 2H, Bn-H2), 6.72 (d, 1H, J=2.0 Hz, 4-H),
6.78 (dd, 1H, J=8.5 Hz, J=2.0 Hz, 2-H), 6.90 (t, 1H, J=7.5 Hz, 5″-
H), 6.98 (d, 1H, J=7.5 Hz, 4″-H), 7.21 (d, 1H, J=8.5 Hz, 1-H), 7.32
(t, 1H, J=7.5 Hz, Bn-4-H), 7.38 (t, 2H, J=7.5 Hz, Bn-3-H and−5-H),
7.45 (m, 3H, Bn-2-H and -6-H), 7.89 (d, 1H, J=7.5 Hz, 6″-H), 10.69 (s,
1H, COOH). 13C NMR (δ, ppm, CDCl3): 11.5 (C-18), 25.9, 27.1, 28.0,
29.3, 37.5, 37.6 (C-8), 39.8 (C-9), 43.5 (C-14), 43.7 (C-13), 48.6 (C-16),
63.6, 68.3, 69.5, 72.0, 81.9 (C-17), 111.8 (C-2), 114.4 (C-4), 117.1,
118.8, 125.9 (C-1), 127.0 (C-2″ and -6″), 127.4 (C-4′), 128.1 (C-3″and
-5″), 129.5, 132.5 (C-10), 135.4, 136.9 (Bn-C-1), 137.5 (C-5), 156.3 (C-
3), 165.3 (C-2″), 169.6 (C-1″).
2.11.5. 3-Benzyloxy-16β-(2′-oxa-4′-azidobutyl)estra-1,3,5(10)-trien-17β-
ol (6e)
Compound 6b (3.30 g, 6mmol) was dissolved in N,N-di-
methylformamide (50ml) and NaN3 (3.30 g, 50.7mmol) was added.
The reaction mixture was stirred for 5 h at 100 °C. It was then diluted
with water and the white precipitate formed was separated by ﬁltration
to give 6e (1.8 g, 65%). Mp: 83–84 °C; Rf = 0.80 (ss B); [α]D25=+36.3
(c 1 in CHCl3). Found: C, 72.71; H, 7.81. C28H35N3O3 (461.60) requires:
C, 72.86; H, 7.64%). 1H NMR (δ, ppm, CDCl3): 0.84 (s, 3H, 18-H3), 2.85
(m, 2H, 6-H2), 3.41–3.88 (overlapping multiplets, 6H, 3× linker H2),
5.04 (s, 2H, Bn-H2), 6.72 (s, 1H, 4-H), 6.78 (dd, 1H, J=8.5 Hz,
J=2.5 Hz, 2-H), 6.79 (d, 1H, J=8.5 Hz, 1-H), 7.33 (d, 1H, J=7.0 Hz,
4′-H), 7.38 (t, 2H, J=7.5 Hz, 3′- and 5′-H), 7.43 (d, 2H, J=7.5 Hz, 2′-
and 6′-H). 13C NMR (δ, ppm, CDCl3): 11.9 (C-18), 26.3, 27.5, 28.4,
29.7, 37.9, 38.0 (C-8), 40.2 (C-9), 43.9 (C-14), 44.1 (C-13), 49.0 (C-16),
50.8 (N-CH2), 69.5 (linker CH2), 69.9 (linker CH2), 72.5 (Bn-CH2), 82.1
(C-17), 112.2 (C-4), 114.8 (C-2), 126.3 (C-2′ and -6′), 127.4 (C-1),
127.8 (C-4′), 128.1 (C-3′ and -5′), 132.9 (C-10), 137.3, 137.9 (C-5),
156.7 (C-3).
2.11.6. 3-Benzyloxy-16β-[2′-oxa-4′(4″-phenyl)1″H-1″,2″,3″-triazol-1″-
yl]butyl-estra-1,3,5(10)-17β-ol (6f)
Compound 6e (461.6 mg, 1mmol) and phenylacetylene (0.22ml)
were used for the synthesis as described in Section 2.8. The crude
product was chromatographed on silica gel with ethyl acetate/CH2Cl2
(2.5:97.5 v/v%) to yield pure 6f (399mg, 71%) as white solid. Mp:
170–171 °C; Rf = 0.60 (ss B); [α]D25=+33.0 (c 1 in CHCl3). (Found:
C, 76.43; H, 7.45. C36H41N3O3 (563.73) requires: C, 76.70; H, 7.33%).
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.80 (m, 2H, 6-H2),
3.68–4.59 (overlapping multiplets, 6H, 3× linker H2), 5.04 (s, 2H, Bn-
H2), 6.71 (d, 1H, J=2.5 Hz, 4-H), 6.78 (dd, 1H, J=8.5 Hz, J=5.5 Hz,
2-H), 7.19 (d, 1H, J=8.5 Hz, 1-H). 13C NMR (δ, ppm, CDCl3): 12.0 (C-
18), 26.3, 27.4, 28.7, 29.7, 37.7, 38.0 (C-8), 40.1 (C-9), 43.8 (C-14),
44.1 (C-13), 48.9 (C-16), 50.3, 69.2, 69.9, 72.6, 82.0 (C-17), 112.2 (C-
2), 114.7 (C-4), 125.6 (C-1′ and -6′), 126.2 (C-1), 127.4 (C-3′ and -5′),
127.8 (C-4′), 128.1 (C-4″), 128.5 (C-2″ and -6″), 128.8 (C-3″ and -5″),
130.5 (C-1′), 132.8 (C-10), 137.2 (C-1″), 137.8 (C-5), 156.7 (C-3).
2.11.7. 3-Benzyloxy-16β-[2′-oxa-4′(4″-p-tolyl)1″H-1″,2″,3″-triazol-1″-
yl]butyl-estra-1,3,5(10)-17β-ol (6 g)
Compound 6e (461.6 mg, 1mmol) and p-tolylacetylene (0.22ml)
were used for the synthesis as described in Section 2.8. The crude
product was chromatographed on silica gel with ethyl acetate/CH2Cl2
(2.5:97 v/v%) to yield pure 6 g (517mg, 90%) as white solid. Mp:
181–183 °C; Rf = 0.50 (ss B); [α]D25=+30.9 (c 1 in CHCl3). (Found:
C, 77.10; H, 7.45. C37H43N3O3 (577.76) requires: C, 76.92; H, 7.50%).
1H NMR (δ, ppm, CDCl3): 0.78 (s, 3H, 18-H3), 2.39 (s, 3H, 4″-H3), 2.80
(m, 2H, 6-H2), 3.52–3.90 (overlapping multiplets, 6H, 3× linker H2),
5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.78 (dd, 1H, J=8.5 Hz,
J=2.5 Hz, 2-H), 7.19 (d, 1H, J=8.5 Hz, 1-H), 7.23 (d, 2H, J=7.5 Hz,
3″- and 5″-H), 7.32 (d, 1H, J=7.0 Hz, triazol H), 7.38 (t, 2H,
J=7.5 Hz, 3′- and 5′-H), 7.43 (d, 2H, J=7.5 Hz, 2′- and 6′-H), 7.73 (d,
2H, J=7.5 Hz, 2″- and 6″-H); 7,86 (s, 1H, 5′-H). 13C NMR (δ, ppm,
CDCl3): 12.0 (C-18), 21.3 (4″-CH3), 27.5, 28.7, 29.7, 37.8, 38.0 (C-8),
40.2 (C-9), 43.9 (C-14), 44.2 (C-13), 48.9 (C-16), 50.3 (N-CH2), 69.3
(linker CH2), 70.0 (linker CH2), 72.7 (Bn-CH2), 82.0 (C-17), 112.2 (C-
2), 114.8 (C-4), 120.3 (triazol CH), 125.6 (C-2′ and -6′), 126.0 (C-1),
127.4 (C-2″ and -6″), 127.7 (C-4′), 127.8 (C-4″), 128.5 (C-3″ and -5″),
129.5 (C-3′ and -5′), 132.8 (C-10), 137.3 (C-1′), 137.9 (C-1″), 143.0
(triazol C), 156.7 (C-3).
2.11.8. 3-Benzyloxy-16β-[2′-oxa-4′(4″-p-methoxyphenyl)1″H-1″,2″,3″-
triazol-1″-yl]butyl-estra-1,3,5(10)-17β-ol (6 h)
Compound 6e (461.6 mg, 1mmol) and p-methoxyphenylacetylene
(0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (5:95 v/v%) to yield pure 6 h (517mg, 98%) as white solid. Mp:
156–158 °C; Rf = 0.55 (ss B); [α]D25=+18.7 (c 1 in CHCl3). (Found:
C, 74.63; H, 7.18. C37H43N3O4 (593.76) requires: C, 74.84; H, 7.30%).
1H NMR (δ, ppm, CDCl3): 0.78 (s, 3H, 18-H3), 2.80 (m, 2H, 6-H2),
3.53–4.57 (overlapping multiplets, 6H, 3× linker H2), 3.84 (s, 3H, 4″-
OCH3), 5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.77 (dd, 1H, J=8.5 Hz,
J=2.0 Hz, 2-H), 7.32 (d, 2H, J=7.0 Hz, 3″- and 5″-H), 7.19 (d, 1H,
J=8.5 Hz, 1-H), 7.37 (t, 2H, J=7.5 Hz, 3′- and 5′-H), 7.42 (d, 2H,
J=7.0 Hz, 2″- and 6″-H), 7.78 (s, 3H, 2′- and 6′-H, triazol H)). 13C
NMR (δ, ppm, CDCl3): 12.0 (C-18), 26.3, 27.5, 28.7, 29.7, 37.8 (N-CH2),
38.0 (C-8), 40.2 (C-9), 43.9 (C-14), 49.0 (C-16), 50.3 (C-13), 55.3 (4″-
OCH3), 69.3 (linker CH2), 69.9 (linker CH2), 72.7 (Bn-CH2), 82.0 (C-
17), 112.2 (C-2), 114.2 (C-2″ and -6″, C-2′ and -6′), 114.8 (C-4), 123.4
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(C-1″), 126.3 (C-1), 127.0 (triazol CH), 127.4 (C-3″ and -5″), 127.8 (Bn-
4), 128.5 (C-3′ and -5′), 130.8 (C-10), 137.3 (triazol C), 137.8 (C-5),
156.7 (C-4″), 159.6 (C-3).
2.12. 3-Benzyloxy-16β-(2′-oxa-4′-amino)butyl-estra-1,3,5(10)-trien-17β-
ol (6i)
Compound 6e (1.80 g, 3.90mmol) was dissolved in ethanol (60ml),
then hydrazine hydrate (98%, 5ml) and Raney nickel (0.80 g) were
added to the solution in small portions. After completion of the reaction
(monitored by TLC), the catalyst was ﬁltered oﬀ and the ﬁltrate was
diluted with water. The white precipitate separating out was ﬁltered
oﬀ, washed and dried to yield 6i (1.53 g, 90%). Mp: 265 °C (decom-
position). Characterization of the compound was performed as its
acetate. Crude compound 3i (218mg, 0.5 mmol) was dissolved the
mixture of pyridine (2ml) and acetic anhydride (2ml) and the solution
was allowed to stand at room temperature for 12 h. The white pre-
cipitate, separating out after dilution with water, was ﬁltered oﬀ, wa-
shed thoroughly with water and dried to provide the acetylated com-
pound (252mg, 97%). Mp: 81–83 °C; Rf = 0.85 (ss B); [α]D25=+18.7
(c 1 in CHCl3). (Found: C, 73.75; H, 8.15. C32H41NO5 (519.67) requires:
C, 73.96; H, 7.95%). 1H NMR (δ, ppm, CDCl3): 0.84 (s, 3H, 18-H3), 2.07
(s, 3H, Ac-H3), 2.20 (s, 3H, Ac-H3), 2.24 (m, 2H, 6-H2), 4.85 (d, 2H,
J=10.0 Hz, 17-H), 5.03 (s, 2H, Bn-H2), 6.27 (brs, 1H, NH), 6.72 (s, 1H,
4-H), 6.78 (dd, 1H, J=8.5 Hz, J=2.5 Hz, 2-H), 7.19 (d, 1H,
J=8.5 Hz, 1-H), 7.32 (d, 1H, J=7.5 Hz, 4′-H), 7.37 (t, 2H, J=7.0 Hz,
3′- and 5′-H), 7.42, (d, 2H, J=7.0 Hz, 2′- and 6′-H). 13C NMR (δ, ppm,
CDCl3): 13.0 (C-18), 21.2 (Ac-CH3), 23.1 (Ac-CH3), 27.4, 29.3, 29.7,
37.5, 37.9 (C-8), 38.1 (C-9), 39.4 (N-CH2), 43.4 (C-13), 43.7 (C-14),
48.7 (C-16), 69.1 (linker CH2), 69.9 (linker CH2), 72.0 (Bn-CH2), 82.0
(C-17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2′- and -6′),
127.8 (C-4′), 128.5 (C-3′ and -6′), 132.5 (C-10), 137.2 (C-1′), 137.8 (C-
5), 156.7 (C-3), 170.3 (C]O), 171.7 (C]O).
2.12.1. 3-Benzyloxy-16β-[2′-oxa-4′(4″-nitro)benzamidobutyl]estra-
1,3,5(10)-trien-17β-ol (6j)
Compound 6i (520mg, 1mmol) and 4-nitrobenzoic acid (167mg,
1mmol) were used for the synthesis as described in Section 2.10. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (10:90 v/v%) to yield pure 6j (234mg, 40%) as yellow solid.
Mp: 147–149 °C; Rf = 0.45 (ss B); [α]D25=−7.9 (c 1 in CHCl3).
(Found: C, 72.18; H, 6.72. C35H40N2O6 (584.70) requires: C, 71.90; H,
6.90%). 1H NMR (δ, ppm, CDCl3): 0.81 (s, 3H, 18-H3), 5.02 (s, 2H, Bn-
H2), 6.71 (s, 1H, 4-H), 6.77 (dd, 1H, J=8.5 Hz, J=2.5 Hz, 2-H), 7.00
(brs, 1H, NH), 7.19 (d, 1H, J=8.5 Hz, 1-H), 7.31 (d, 1H, J=7.0 Hz, 4′-
H), 7.37 (t, 2H, J=7.0 Hz, 3′- and 5′-H), 7.42 (d, 2H, J=7.0 Hz, 2′ and
6′-H), 7.98 (m, 2H, 3″- and 5″-H), 8.26 (m, 2H, 2″- and 6″-H). 13C NMR
(δ, ppm, CDCl3): 12.1 (C-18), 26.3, 27.5, 28.4, 29.7, 37.8, 38.0 (C-8),
39.9 (C-9), 39.9 (N-CH2), 43.8 (C-14), 44.2 (C-13), 48.9 (C-16), 69.2
(linker CH2), 69.9 (linker CH2), 72.3 (Bn-CH2), 82.4 (C-17), 112.3 (C-
2), 114.8 (C-4), 123.7 (C-2″ and -6″), 126.3 (C-1), 127.4 (C-2′ and -6′),
127.8 (C-4′), 128.3 (C-3′- and -5′), 128.5 (C-3″- and -5″), 130.9 (C-10),
137.3 (C-1″), 137.8 (C-5), 140.0 (C-1′) 156.7 (C-3), 165.5 (C]O).
2.12.2. 3-Benzyloxy-16β-[2′-oxa-4′(3″,5″-dinitro)benzamidobutyl]-estra-
1,3,5(10)-trien-17β-ol (6 k)
Compound 6i (436mg, 1mmol) and 3,5-dinitrobenzoic acid
(212mg, 1mmol) were used for the synthesis as described in Section
2.10. The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (10:90 v/v) to yield pure 6 k (234mg, 40%) as yellow
solid. Mp: 225–227 °C; Rf = 0.45 (ss B); [α]D25=+15.7 (c 1 in CHCl3).
(Found: C, 66.73; H, 6.38. C35H39N3O8 (584.70) requires: C, 66.76; H,
6.24%). 1H NMR (δ, ppm, CDCl3): 0.82 (s, 3H, 18-H3), 5.02 (d, 2H,
J=8.5 Hz, Bn-H2), 6.73 (s, 1H, 4-H), 6.78 (t, 1H, J=2.5 Hz, 2-H), 7.19
(t, 1H, J=8.5 Hz, 1-H), 7.32 (t, 1H, J=7.0 Hz, 4′-H), 7.39 (t, 2H,
J=7.0 Hz, 3′- and 5′-H), 7.46 (t, 2H, J=7.0 Hz, 2′- and 6′-H), 7.50 (s,
1H, 4″-H), 8.29 (brs, 1H, NH), 9.10 and 9.20 (2× s, 2×1H, 2″- and 6″-
H).
2.12.3. 3-Benzyloxy-16β-[2′-oxa-4′(4″-methoxy)benzamido]butyl-estra-
1,3,5(10)-trien-17β-ol (6 l)
Compound 6i (436mg, 1mmol) and 4-methoxybenzoic acid
(152mg, 1mmol) were used for the synthesis as described in Section
2.10. The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (2.5:97.5 v/v%) to yield pure 6 l (279mg, 49%) as
white solid. Mp: 71–73 °C, Rf = 0.50 (ss B); [α]D25=−17.0 (c 1 in
CHCl3). (Found: C, 75.72; H, 7.81. C36H43NO5 (569.73) requires: C,
75.89; H, 7.61%). 1H NMR (δ, ppm, CDCl3): 0.82 (s, 3H, 18-H3), 2.83
(m, 2H, 6-H2), 3.56–3.70 (overlapping multiplets, 6H, 3× linker H2),
3.84 (s, 3H, 4″-OCH3), 5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.78 (d,
1H, J=8.0 Hz, 2-H), 6.91 (d, 1H, J=8.0 Hz, 3″- and 5″-H), 7.20 (d,
1H, J=8.5 Hz, 1-H), 7.32 (d, 1H, J=7.0 Hz, 4′-H), 7.37 (t, 2H,
J=7.0 Hz, 3′- and 5′-H), 7.42 (d, 2H, J=7.0 Hz, 2′- and 6′-H), 7.76 (d,
2H, J=7.5 Hz, 2″- és 6″-H). 13C NMR (δ, ppm, CDCl3): 12.1 (C-18),
26.3, 27.5, 28.5, 29.7, 37.8, 38.1 (C-8), 39.7 (N-CH2), 40.0 (C-9), 43.9
(C-14), 44.2 (C-13), 49.0 (C-16), 55.4 (4″-OCH3) 69.7 (linker CH2), 69.9
(linker CH2), 72.3 (Bn-CH2), 82.3 (C-17), 112.2 (C-2), 113.7 (C-2″- and
-6″), 114.8 (C-4), 126.3 (C-1), 126.6 (C-1′), 127.4 (C-2′ and -6′), 127.8
(C-4′), 128.5 (C-3′ and -5′), 128.7 (C-3″ and -5″), 132.8 (C-10), 137.3
(C-1″), 137.9 (C-5), 156.7 (C-3), 162.2 (C-4″), 167.2 (C]O).
2.12.4. 3-Benzyloxy-16β-[2′-oxa-4′(3″,4″,5″-trimethoxy)benzamido]
butyl-estra-1,3,5(10)-trien-17β-ol (6m)
Compound 6i (436mg, 1mmol) and 3,4,5-trimethoxybenzoic acid
(212mg, 1mmol) were used for the synthesis as described in Section
2.10. The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (10:90 v/v%) to yield pure 6m (485mg, 77%) as white
solid. Mp: 57–59 °C Rf = 0.45 (ss B); [α]D25=−5 (c 1 in CHCl3).
(Found: C, 72.64; H, 7.72. C38H47NO7 (629.70) requires: C, 72.47; H,
7.52%). 1H NMR (δ, ppm, CDCl3): 0.88 (s, 3H, 18-H3), 2.83 (d, 2H,
J=5.5 Hz, 6-H2), 3.50 (m, 6H, 3× linker H2), 3.87 (s, 9H, 3×OCH3),
5.02 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.76 (d, 1H, J=2.0 Hz, 2-H),
7.05 (s, 2H, 2″- and 6″-H), 7.35 (m, 5H, 2′-, 3′-, 4′-, 5′- and 6′-H). 13C
NMR (δ, ppm, CDCl3): 12.1 (C-18), 14.1, 22.6, 26.2, 27.5, 29.6, 37.8,
38.1 (C-8), 39.7 (C-9), 39.8, 43.8 (C-14), 49.0 (C-16), 69.5 (linker CH2),
69.9 (linker CH2), 72.3 (linker CH2), 82.4 (C-17), 104.4, 107.3, 112.3,
114.8, 126.3, 127.4, 127.8, 128.5, 129.6, 132.8, 153.2, 156.8, 167.4
(C]O).
2.13. Determination of the antiproliferative activities
The growth-inhibitory eﬀects of the compounds were tested in vitro
by means of an MTT assay on a panel containing four breast cancer lines
(MCF-7, MDA-MB-231), a cervical and an ovarian cancer cell lines
(SiHa and A2780).
The cell lines were obtained from the European Collection of Cell
Cultures (Salisbury, UK). The cells were maintained in minimal essen-
tial medium supplemented with 10% fetal bovine serum (FBS), 1% non-
essential amino acids and an antibiotic–antimycotic mixture (AAM). All
chemicals, if otherwise not speciﬁed, were purchased from Sigma-
Aldrich Ltd. (Budapest, Hungary). All cell lines were grown in a hu-
midiﬁed atmosphere of 5% CO2 at 37 °C. For pharmacological in-
vestigations, 10mM stock solutions of the tested compounds were
prepared with dimethyl sulfoxide (DMSO). The highest applied DMSO
concentration of the medium (0.3%) did not have any substantial eﬀect
on the determined cellular functions. All cell types were seeded into 96-
well plates at a density of 5000 cells/well and allowed to stand over-
night under cell culturing conditions, and the medium containing the
tested compound was then added. After a 72-h incubation with two
concentrations (10 and 30 µM) of the compounds, viability was de-
termined by the addition of 20 µl 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) solution (5mg/ml) for 4 h [9]. The
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precipitated formazan crystals were solubilized in DMSO and the ab-
sorbance was determined at 545 nm with an ELISA reader; wells with
untreated cells were utilized as controls. Two independent experiments
were performed with 5 parallel wells. Cisplatin, an agent administered
clinically in the treatment of certain gynecological malignancies, was
used as positive control in the same concentration range as the test
compounds. For the most eﬀective compounds, the assays were re-
peated with a set of dilutions (0.03–30 µM), and sigmoidal dose–r-
esponse curves were ﬁtted to the measured data in order to determine
the IC50 values by means of Graphpad Prism 4.0 (Graphpad Software;
San Diego, CA, US).
3. Results and discussion
3.1. Synthetic studies
To prepare novel steroid hybrid systems, 3-methoxy-16β-p-to-
lylsulfonyloxymethyl-estra-1,3,5(10)-trien-17β-ol (1) [4] and 3-benzy-
loxy-16β-bromomethyl-estra-1,3,5(10)-tien-17β-ol (4) [7] were se-
lected as starting compounds. The synthetic strategy for the preparation
of 3-methoxy- and 3-bezyloxy-16β-(2′-oxa-4′-hydroxybutyl),17β-hy-
droxy-estra-1,3,5(10)-trienes (3a and 6a) is illustrated in Scheme 1.
The alkaline methanolysis of 1 and 4 resulted in the formation of 3-
methoxy- and 3-benzyloxy-17β,16β-epoxymethylen-estra-1,3,5(10)-
trienes 2 and 5. The process can be regarded as neighbouring group
participation characterized by the general symbol (OØ-4). Oxethane
formation takes place readily when the participating groups are in a
favourable steric conﬁguration [5,6]. Compounds 2 and 5 in ethylene
glycol in the presence of a catalytic amount of BF3.OEt2 were converted
in fast reactions to aﬀord required 3a and 6a in quantitative yields
without any rearrangement byproducts.
Iodination of 3a and 6a by the Appel reaction gave terminal iodo
compounds 3b and 6b in good yields. Regioselective one-pot 3-O-al-
kylation with unprotected ascorbic acid was achieved using 3b and 6b
in the presence of NaHCO3 in DMSO to yield 3c and 6c. The same
process with salicylic acid led to 2-O-alkylated salicylic acid derivatives
3d and 6d. Iodo derivatives 3b and 6b via nucleophilic exchange re-
action with NaN3 in N,N-dimethylformamide furnished the corre-
sponding azido compounds 3e and 6e. These were then subjected to
azide–alkyne CuAAC reactions with phenylacetylene and p-substituted
derivatives [8]. CuAAC of 3e and 6e were carried out in reﬂuxing
CH2Cl2 with CuI as catalyst in the presence of Et3N to obtain the re-
quired 1,4-substituted triazoles (3f-h and 6f-h) in good yields in 12 h.
The reduction of 3e and 6e in ethanol with hydrazine hydrate in the
presence of a catalytic amount of Raney Ni furnished the corresponding
amino derivatives 3i and 6i. These compounds were reacted further
with 4-nitro-, 3,5-dinitro-, 4-methoxy-, and 3,4,5-trimethoxy benzoic
acid in the presence of HOBT (1-hydroxy-benzotriazol hydrate), HBTU
[(O-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexaﬂuoropho-
sphate] and DIPEA to yield the corresponding terminal aromatic ben-
zamido derivatives 3j-m and 6j-m. (Scheme 2)
3.2. Determination of the antiproliferative properties of the 3-methoxy-, and
3-benzyloxy-16β-[(2′-oxa-4′-hydroxy)butyl-17β-hydroxy-estra-1,3,5(10)-
trien-17β-ols
The antiproliferative activities of compounds 3a-m and 6a–m were
determined in vitro by means of MTT assays against human adherent
cancer cell lines of gynecological origin including A2780 (ovarian
carcinoma), MCF-7(breast cancer, expressing estrogen and proges-
terone receptors), MDA-MB-231 (breast cancer, triple-negative) and
SiHa (cervical carcinoma, human papillomavirus-16 positive).
The two epoxymethylene compounds (2 and 5) inﬂuenced the
growth of the cell linesscarcely (Table 1). The ring opening of the cyclic
ethers led to derivatives 3a and 6a with increased antiproliferative
potential, especially in the 3-benzyl ether series. The iodination of the
hydroxyl function resulted in compounds 3b and 6b with decreased cell
growth-inhibitory action. The covalent coupling of the steroids with
ascorbic or salicylic acid derivatives proved to be advantageous, since
hybrids 3c,d and 6c,d proved to be comparable to reference agent
cisplatin against some of the used cells (A2780 and MCF-7). These
conjugates displayed the most selective inhibitory action concerning
the diﬀerent cancer cell lines. Their IC50 values for the triple negative
breast cancer line (MDA-MB-231) are one order of magnitude higher
than those obtained for A2780 and MCF-7.
Azidation of the terminal hydroxyl function resulted in compounds
3e and 6e with moderate antiproliferative action only for the 3-benzyl
ether counterpart (6e). This eﬀect could not be intensiﬁed by clicking
terminal alkynes on steroidal azides (3e, 6e). Concerning compounds
3f-h, IC50 values under 10 µM have not been observed. Contrarily, the
reduction of the azide function resulted in terminal amines 3i and 6i
with substantial cell growth-inhibitory properties.
In order to obtain data concerning the cancer selectivity of the
amines 3i and 6i, in vitro MTT assays against MCF-5 cell line (non-
cancerous human ﬁbroblast) were performed (Table 2). The calculated
IC50 values of 3i and 6i proved to be 2.7 and 2.5 µM, respectively, while
that of reference agent cisplatin was 6.2 µM, indicating that these mo-
lecules inﬂuence the proliferation of the determined cancer cells
without any cancer selectivity. The data reveal that 3i and 6i and exert
their cell growth-inhibitory action against cancer cell lines and ﬁbro-
blast in the same concentration range.
The further functionalization of the amines (3i and 6i) led to amino
derivatives 3j-m with decreased antiproliferative potential. It can be
stated that the presence of two nitro substituents on the newly in-
troduced phenyl ring is more advantageous than that of methoxy
groups.
Our current experimental results demonstrate that 3c, 3d, 6c and 6d
may be considered as potent antiproliferative properties against human
cancer cell lines. Though further development of these agents however,
seems to be limited by their non-selective character the generated data
could be utilized in an optimization procedure in order to obtain si-
milarly eﬀective, but more selective hybrid molecules.
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